Hoja de referencia de péptidos
Tamaños de los viales y concentración (mg/mL) que se obtienen después de agregar 1, 2 o 3 ml de agua bacteriostática. Sin dosis: use el calculadora con tus propias cifras. Uso exclusivo en investigación.
| Compuesto | Frasco | 1 ml → mg/ml | 2 ml → mg/ml | 3 ml → mg/ml |
|---|---|---|---|---|
| 5-Amino-1MQ NNMT inhibitor | 10 mg | 10 | 5 | 3.33 |
| 50 mg | 50 | 25 | 16.67 | |
| Adamax Supplier-described Semax analogue; exact structure unconfirmed | 10 mg | 10 | 5 | 3.33 |
| AICAR Acadesine | 50 mg | 50 | 25 | 16.67 |
| AOD-9604 Tyr-hGH(177–191), modified hGH C-terminal fragment | 2 mg | 2 | 1 | 0.67 |
| 5 mg | 5 | 2.5 | 1.67 | |
| AOD-9604 + CJC-1295 + Ipamorelin | 12 mg | 12 | 6 | 4 |
| ARA-290 Cibinetide | 10 mg | 10 | 5 | 3.33 |
| BPC-157 Body Protection Compound-157 | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| Cagrilintide Long-acting amylin analog | 5 mg | 5 | 2.5 | 1.67 |
| Cagrilintide + Retatrutide | 10 mg | 10 | 5 | 3.33 |
| Cagrilintide + Semaglutide Componentes estudiados juntos como CagriSema; la mezcla del catálogo no es la formulación del ensayo | 10 mg | 10 | 5 | 3.33 |
| Cagrilintide + Tirzepatide | 10 mg | 10 | 5 | 3.33 |
| Cartalax AED tripeptide | 10 mg | 10 | 5 | 3.33 |
| 20 mg | 20 | 10 | 6.67 | |
| CJC-1295 / Ipamorelin GHRH + GHRP blend (no DAC) | 10 mg | 10 | 5 | 3.33 |
| CJC-1295 + GHRP-2 | 10 mg | 10 | 5 | 3.33 |
| CJC-1295 DAC GHRH analog with Drug Affinity Complex | 2 mg | 2 | 1 | 0.67 |
| DSIP Delta sleep-inducing peptide | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| Epitalon Epithalon, AEDG | 10 mg | 10 | 5 | 3.33 |
| 50 mg | 50 | 25 | 16.67 | |
| FOXO4-DRI | 10 mg | 10 | 5 | 3.33 |
| GHK-Cu Copper tripeptide-1 | 50 mg | 50 | 25 | 16.67 |
| 100 mg | 100 | 50 | 33.33 | |
| GHRP-6 Growth hormone releasing peptide-6 | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| GLOW GHK-Cu + BPC-157 + TB-500 | 70 mg | 70 | 35 | 23.33 |
| Glutathione GSH | 500 mg | 500 | 250 | 166.67 |
| 1000 mg | 1,000 | 500 | 333.33 | |
| Humanin | 10 mg | 10 | 5 | 3.33 |
| IGF-1 LR3 Long R3 IGF-1 | 1 mg | 1 | 0.5 | 0.33 |
| Ipamorelin | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| Ipamorelin + Tesamorelin | 10 mg | 10 | 5 | 3.33 |
| Kisspeptin-10 Kp-10 | 10 mg | 10 | 5 | 3.33 |
| KLOW KPV + GHK-Cu + BPC-157 + TB-500 | 80 mg | 80 | 40 | 26.67 |
| KPV α-MSH(11-13) | 10 mg | 10 | 5 | 3.33 |
| Melanotan II MT-II | 10 mg | 10 | 5 | 3.33 |
| MOTS-c | 10 mg | 10 | 5 | 3.33 |
| 40 mg | 40 | 20 | 13.33 | |
| NAD+ Nicotinamide adenine dinucleotide | 500 mg | 500 | 250 | 166.67 |
| 1000 mg | 1,000 | 500 | 333.33 | |
| Oxytocin | 2 mg | 2 | 1 | 0.67 |
| 5 mg | 5 | 2.5 | 1.67 | |
| PT-141 Bremelanotide | 10 mg | 10 | 5 | 3.33 |
| Retatrutide GIP / GLP-1 / glucagon triple agonist | 10 mg | 10 | 5 | 3.33 |
| 20 mg | 20 | 10 | 6.67 | |
| 30 mg | 30 | 15 | 10 | |
| Selank | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| Semaglutide GLP-1 agonist | 3 mg | 3 | 1.5 | 1 |
| 5 mg | 5 | 2.5 | 1.67 | |
| 10 mg | 10 | 5 | 3.33 | |
| Semax | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| Sermorelin GHRH(1-29) | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| SLU-PP-332 ERR agonist | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| SS-31 Elamipretide | 10 mg | 10 | 5 | 3.33 |
| 50 mg | 50 | 25 | 16.67 | |
| Survodutide GLP-1 / glucagon dual agonist | 10 mg | 10 | 5 | 3.33 |
| 20 mg | 20 | 10 | 6.67 | |
| TB-500 Supplier-dependent thymosin β4-related product | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| Tesamorelin GHRH analog | 10 mg | 10 | 5 | 3.33 |
| 20 mg | 20 | 10 | 6.67 | |
| Tesofensine | 10 mg | 10 | 5 | 3.33 |
| Thymosin Alpha-1 Tα1 | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| Tirzepatide GIP / GLP-1 dual agonist | 10 mg | 10 | 5 | 3.33 |
| 15 mg | 15 | 7.5 | 5 | |
| 30 mg | 30 | 15 | 10 | |
| Tri-Heal TB-500 + BPC-157 + KPV | 45 mg | 45 | 22.5 | 15 |
| VIP Vasoactive intestinal peptide | 5 mg | 5 | 2.5 | 1.67 |
| 10 mg | 10 | 5 | 3.33 | |
| Wolverine Blend BPC-157 + TB-500 | 20 mg | 20 | 10 | 6.67 |
Los tamaños de los viales son referencias reportadas por el mercado, no verificación del contenido de ningún producto.